---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-25-000002"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2025-01-06T23:59:59+00:00"
generated_at: "2026-05-28T10:40:08.293204+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AbbVie reports $1.574B Q4 IPR&D charge, cuts adjusted EPS guidance by $0.88

## Summary
- Expected Q4 2024 acquired IPR&D and milestones expense of $1,574M pre-tax, $0.88 per share impact.
- Adjusted diluted EPS guidance for Q4 2024 revised to $2.06-$2.10 (from $2.94-$2.98).
- Full-year 2024 adjusted diluted EPS guidance revised to $10.02-$10.06 (from $10.90-$10.94).
- Previous guidance excluded Q4 IPR&D expense; company does not forecast such expenses.
- Q4 2024 results not finalized; subject to closing procedures.

## SEC filing metadata
- accession: 0001551152-25-000002
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2025-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000002/0001551152-25-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000002/abbv-20250106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-25-000002
- JSON: https://secwatch.observer/filing/0001551152-25-000002.json
- Plain text: https://secwatch.observer/filing/0001551152-25-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.